Procter & Gamble Health Ltd
Procter & Gamble Health Ltd develops, manufactures, and markets consumer healthcare products, including over-the-counter medications and personal care items.
Business. Procter & Gamble Health Ltd (PROR.NS) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on the development and sale of pharmaceutical products. It is primarily listed on the National Stock Exchange of India. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Procter & Gamble Health Ltd (PROR.NS) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on the development and sale of pharmaceutical products. It is primarily listed on the National Stock Exchange of India. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
The company maintains a strong liquidity position, with a current ratio of 2.44 and cash and equivalents of INR 898.1 million, indicating a solid ability to meet short-term obligations. The low debt-to-equity ratio of 0.01 suggests a conservative capital structure, with minimal reliance on long-term debt. This aligns with the industry preference for low leverage and strong equity positions.
Profitability metrics show a return on equity of 43.66% and a return on assets of 29.52%, both significantly above the typical thresholds for pharmaceutical firms. The gross profit margin of 66.04% (calculated from revenue and gross profit) and an operating margin of 32.30% (calculated from operating income) further highlight the company's strong pricing power and cost control.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the firm operates primarily in India, with no disclosed international revenue streams. This concentration may expose the company to regional economic and regulatory risks.
The company's revenue growth is expected to remain stable, with no significant changes projected in the current or next fiscal year. Historical revenue of INR 9.34 billion provides a baseline for future performance, though the absence of growth drivers or new product launches in the data suggests a conservative outlook.
Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based flags were detected, and the company's capital structure remains stable. The absence of dilution risk is supported by the identical basic and diluted share counts, indicating no near-term pressure from share issuance.
Recent events include the latest financial filing (market data), which provides the most recent snapshot of the company's financial position. No recent earnings call transcripts or regulatory filings were identified in the available data.
- Procter & Gamble Health Ltd maintains a conservative capital structure with minimal debt and strong liquidity.
- The company's profitability metrics, including ROE and ROA, are well above industry norms.
- Revenue is concentrated in a single business segment and geographic region, increasing exposure to local market risks.
- No immediate liquidity or dilution risks are present, and the capital structure remains stable.
- The company's growth trajectory is expected to remain flat, with no significant changes in revenue or operating performance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Procter & Gamble Health Ltd Market data — financials · 2026-05-29
- Procter & Gamble Health Ltd Market data — analyst estimates · 2026-05-29
- Procter & Gamble Health Ltd Market data — ESG · 2026-05-29